These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11459336)

  • 21. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes?
    Nierenberg AA; Pava JA; Clancy K; Rosenbaum JF; Fava M
    Biol Psychiatry; 1996 Oct; 40(8):691-6. PubMed ID: 8894060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of recurrent brief depression with reboxetine -- a single case analysis.
    Pezawas L; Stamenkovic M; Aschauer N; Moffat R; Kasper S
    Pharmacopsychiatry; 2002 Mar; 35(2):75-6. PubMed ID: 11951149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoxetine versus trazodone in the treatment of outpatients with major depression.
    Debus JR; Rush AJ; Himmel C; Tyler D; Polatin P; Weissenburger J
    J Clin Psychiatry; 1988 Nov; 49(11):422-6. PubMed ID: 3053668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Zurich Study--a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. IV. Recurrent and nonrecurrent brief depression.
    Angst J; Dobler-Mikola A
    Eur Arch Psychiatry Neurol Sci; 1985; 234(6):408-16. PubMed ID: 3875489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.
    Emslie GJ; Rush AJ; Weinberg WA; Kowatch RA; Hughes CW; Carmody T; Rintelmann J
    Arch Gen Psychiatry; 1997 Nov; 54(11):1031-7. PubMed ID: 9366660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the efficacy and tolerability of fluoxetine in major depression, Multicenter clinical study].
    Cabras PL; Enriques E; Casini A; Paoletti C; Zagnoni P
    Minerva Psichiatr; 1991; 32(2):93-101. PubMed ID: 1870418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluoxetine treatment of dysthymia in the elderly.
    Nobler MS; Devanand DP; Kim MK; Fitzsimons LM; Singer TM; Turret N; Sackeim HA; Roose SP
    J Clin Psychiatry; 1996 Jun; 57(6):254-6. PubMed ID: 8666563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personality disorder comorbidity with major depression and response to fluoxetine treatment.
    Fava M; Bouffides E; Pava JA; McCarthy MK; Steingard RJ; Rosenbaum JF
    Psychother Psychosom; 1994; 62(3-4):160-7. PubMed ID: 7846259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.
    Tzanakaki M; Guazzelli M; Nimatoudis I; Zissis NP; Smeraldi E; Rizzo F
    Int Clin Psychopharmacol; 2000 Jan; 15(1):29-34. PubMed ID: 10836283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
    Versiani M; Moreno R; Ramakers-van Moorsel CJ; Schutte AJ;
    CNS Drugs; 2005; 19(2):137-46. PubMed ID: 15697327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine.
    Simon GE; Heiligenstein JH; Grothaus L; Katon W; Revicki D
    J Clin Psychiatry; 1998 Feb; 59(2):49-55. PubMed ID: 9501885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoxetine versus placebo in depressed alcoholic cocaine abusers.
    Cornelius JR; Salloum IM; Thase ME; Haskett RF; Daley DC; Jones-Barlock A; Upsher C; Perel JM
    Psychopharmacol Bull; 1998; 34(1):117-21. PubMed ID: 9564208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Double-blind study of mianserin and fluoxetine in ambulatory therapy of depressed patients].
    Besançon G; Cousin R; Guitton B; Lavergne F
    Encephale; 1993; 19(4):341-5. PubMed ID: 8275922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How long should patients with psychotic depression stay on the antipsychotic medication?
    Rothschild AJ; Duval SE
    J Clin Psychiatry; 2003 Apr; 64(4):390-6. PubMed ID: 12716238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of recurrent brief depression in primary care.
    Weiller E; Boyer P; Lepine JP; Lecrubier Y
    Eur Arch Psychiatry Clin Neurosci; 1994; 244(4):174-81. PubMed ID: 7888414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis.
    Zajecka JM; Jeffries H; Fawcett J
    J Clin Psychiatry; 1995 Aug; 56(8):338-43. PubMed ID: 7635848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of fluoxetine and doxepin in treatment of melancholia in depressed patients.
    Sandor P; Baker B; Irvine J; Dorian P; McKessok D; Mendlowitz S
    Depress Anxiety; 1998; 7(2):69-72. PubMed ID: 9614594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    Silverstone PH; Ravindran A
    J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The phenomenology of recurrent brief depression with and without hypomanic features.
    Lövdahl H; Andersson S; Hynnekleiv T; Malt UF
    J Affect Disord; 2009 Jan; 112(1-3):151-64. PubMed ID: 18538858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.